{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:55:09Z","timestamp":1791269709343,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05983-6","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:37:37Z","timestamp":1791268657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse drug reactions to first-line anti-tuberculosis treatments, associated factors, and treatment outcomes: a retrospective study from Southern Morocco"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-6384","authenticated-orcid":false,"given":"Omar","family":"Er-Rguibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnae","family":"Dahdah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Saou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"5983_CR1","doi-asserted-by":"publisher","unstructured":"American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America (2005) Controlling tuberculosis in the United States. Am J Respir Crit Care Med 172:1169\u20131227. https:\/\/doi.org\/10.1164\/rccm.2508001","DOI":"10.1164\/rccm.2508001"},{"key":"5983_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227101","volume":"14","author":"MB Arriaga","year":"2019","unstructured":"Arriaga MB, Torres NMC, Araujo NCN, Caldas SCC, Andrade BB, Netto EM (2019) Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: a retrospective cohort study. PLoS ONE 14:e0227101. https:\/\/doi.org\/10.1371\/journal.pone.0227101","journal-title":"PLoS ONE"},{"key":"5983_CR3","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/MJT.0b013e3181c0806d","volume":"18","author":"P Baghaei","year":"2011","unstructured":"Baghaei P, Tabarsi P, Dorriz D, Marjani M, Shamaei M, Pooramiri MV et al (2011) Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther 18:e29\u2013e34. https:\/\/doi.org\/10.1097\/MJT.0b013e3181c0806d","journal-title":"Am J Ther"},{"key":"5983_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12900","volume":"71","author":"CL Baker","year":"2017","unstructured":"Baker CL, Flores NM, Zou KH, Bruno M, Harrison VJ (2017) Benefits of quitting smoking on work productivity and activity impairment in the United States, the European Union and China. Int J Clin Pract 71:e12900. https:\/\/doi.org\/10.1111\/ijcp.12900","journal-title":"Int J Clin Pract"},{"key":"5983_CR5","doi-asserted-by":"publisher","first-page":"0","DOI":"10.23750\/abm.v96i2.16457","volume":"96","author":"M Belomaria","year":"2025","unstructured":"Belomaria M, El Bakkali M, Bouchefra S, Bouazza G, Rektouti M, Ouhssine M (2025) Tuberculosis treatment-related adverse events and associated risk factors: insights from a retrospective cohort in Morocco. Acta Biomed 96:0\u201314. https:\/\/doi.org\/10.23750\/abm.v96i2.16457","journal-title":"Acta Biomed"},{"key":"5983_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.37897\/RJID.2024.4.9","volume":"27","author":"M Belomaria","year":"2024","unstructured":"Belomaria M, El Bakkali M, Bouchefra S, Rektouti M, Bouazza G, Ouhssine M (2024) Retrospective study of side effects of anti-tuberculosis medications and modeling of the cumulative effect of risk factors. Rom J Infect Dis 27:304\u2013311. https:\/\/doi.org\/10.37897\/RJID.2024.4.9","journal-title":"Rom J Infect Dis"},{"key":"5983_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.rppnen.2014.08.004","volume":"21","author":"AT Castro","year":"2015","unstructured":"Castro AT, Mendes M, Freitas S, Roxo PC (2015) Incidence and risk factors of major toxicity associated with first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years. Rev Port Pneumol (Engl Ed) 21:144\u2013150. https:\/\/doi.org\/10.1016\/j.rppnen.2014.08.004","journal-title":"Rev Port Pneumol (Engl Ed)"},{"key":"5983_CR8","first-page":"531","volume":"58","author":"AK Chhetri","year":"2008","unstructured":"Chhetri AK, Saha A, Verma SC, Palaian S, Mishra P, Shankar PR (2008) Study of adverse drug reactions caused by first-line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara. J Pak Med Assoc 58:531\u2013536","journal-title":"J Pak Med Assoc"},{"key":"5983_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/pds.5513","volume":"31","author":"H Choi","year":"2022","unstructured":"Choi H, Park HA, Hyun IG, Kim J, Hwang Y, Jang SH et al (2022) Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: a multicenter prospective cohort study. Pharmacoepidemiol Drug Saf 31:1153\u20131163. https:\/\/doi.org\/10.1002\/pds.5513","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5983_CR10","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3390\/jcm14072154","volume":"14","author":"R Cioboata","year":"2025","unstructured":"Cioboata R, Balteanu MA, Osman A, Vlasceanu SG, Zlatian OM, Mitroi DM et al (2025) Coinfections in tuberculosis in low- and middle-income countries: epidemiology, clinical implications, diagnostic challenges, and management strategies\u2014a narrative review. J Clin Med 14:2154. https:\/\/doi.org\/10.3390\/jcm14072154","journal-title":"J Clin Med"},{"key":"5983_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40545-023-00577-6","volume":"16","author":"RDA Djochie","year":"2023","unstructured":"Djochie RDA, Anto BP, Opare-Addo MNA (2023) Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study. J Pharm Policy Pract 16:1\u201310. https:\/\/doi.org\/10.1186\/s40545-023-00577-6","journal-title":"J Pharm Policy Pract"},{"key":"5983_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12879-019-3931-5","volume":"19","author":"M El Hamdouni","year":"2019","unstructured":"El Hamdouni M, Bourkadi JE, Benamor J, Hassar M, Cherrah Y, Ahid S (2019) Treatment outcomes of drug-resistant tuberculosis patients in Morocco: a multicentric prospective study. BMC Infect Dis 19:316. https:\/\/doi.org\/10.1186\/s12879-019-3931-5","journal-title":"BMC Infect Dis"},{"key":"5983_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s15010-019-01324-3","volume":"48","author":"M El Hamdouni","year":"2020","unstructured":"El Hamdouni M, Ahid S, Bourkadi JE, Benamor J, Hassar M, Cherrah Y (2020) Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco. Infection 48:43\u201350. https:\/\/doi.org\/10.1007\/s15010-019-01324-3","journal-title":"Infection"},{"key":"5983_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/412893","volume":"2014","author":"A Farazi","year":"2014","unstructured":"Farazi A, Sofian M, Jabbariasl M, Keshavarz S (2014) Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat 2014:412893. https:\/\/doi.org\/10.1155\/2014\/412893","journal-title":"Tuberc Res Treat"},{"key":"5983_CR15","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.11622\/smedj.2013097","volume":"54","author":"V Gerdan","year":"2013","unstructured":"Gerdan V, Akko\u00e7 N, Ucan E, Bula\u00e7 Kir S (2013) Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia. Singapore Med J 54:e125\u2013e126. https:\/\/doi.org\/10.11622\/smedj.2013097","journal-title":"Singapore Med J"},{"key":"5983_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/v13050931","volume":"13","author":"CM Gonz\u00e1lez-Domenech","year":"2021","unstructured":"Gonz\u00e1lez-Domenech CM, P\u00e9rez-Hern\u00e1ndez I, G\u00f3mez-Ayerbe C, Viciana Ramos I, Palacios-Mu\u00f1oz R, Santos J (2021) A pandemic within other pandemics: when a multiple infection of a host occurs: SARS-CoV-2, HIV and Mycobacterium tuberculosis. Viruses 13:931. https:\/\/doi.org\/10.3390\/v13050931","journal-title":"Viruses"},{"key":"5983_CR17","unstructured":"Haut-Commissariat au Plan (2020) Monographie de la r\u00e9gion La\u00e2youne-Sakia El Hamra 2020. Haut-Commissariat au Plan, Rabat. Available at: https:\/\/www.hcp.ma\/region-laayoune\/Monographie-de-la-Region-Laayoune-Sakia-EL-Hamra-2020_a79.html. Accessed 02 Aug 2025"},{"key":"5983_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00009","volume":"137","author":"RM Jasmer","year":"2002","unstructured":"Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E et al (2002) Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 137:640\u2013647. https:\/\/doi.org\/10.7326\/0003-4819-137-8-200210150-00009","journal-title":"Ann Intern Med"},{"key":"5983_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/pds.1468","volume":"16","author":"MR Javadi","year":"2007","unstructured":"Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, Mirsaeedi SM (2007) Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf 16:1104\u20131110. https:\/\/doi.org\/10.1002\/pds.1468","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5983_CR20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.5588\/ijtld.15.0318","volume":"20","author":"AM Kelly","year":"2016","unstructured":"Kelly AM, Smith B, Luo Z, Given B, Wehrwein T, Master I et al (2016) Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment. Int J Tuberc Lung Dis 20:442\u2013447. https:\/\/doi.org\/10.5588\/ijtld.15.0318","journal-title":"Int J Tuberc Lung Dis"},{"key":"5983_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065037","volume":"8","author":"X Lv","year":"2013","unstructured":"Lv X, Tang S, Xia Y, Wang X, Yuan Y, Hu D et al (2013) Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS ONE 8:e65037. https:\/\/doi.org\/10.1371\/journal.pone.0065037","journal-title":"PLoS ONE"},{"key":"5983_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10096-019-03489-z","volume":"38","author":"Y Ma","year":"2019","unstructured":"Ma Y, Che N-Y, Liu Y-H, Shu W, Du J, Xie S-H et al (2019) The joint impact of smoking plus alcohol drinking on treatment of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis 38:651\u2013657. https:\/\/doi.org\/10.1007\/s10096-019-03489-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5983_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SHD (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x","journal-title":"Br J Clin Pharmacol"},{"key":"5983_CR24","doi-asserted-by":"publisher","unstructured":"Mate K, Mishra G, Munje R (2022) Adverse drug reactions to a daily fixed-dose combination-based antituberculosis treatment regimen in India\u2019s national tuberculosis elimination programme: a prospective cohort study. J Clin Diagn Res 16:OC14\u2013OC19. https:\/\/doi.org\/10.7860\/JCDR\/2022\/57878.16719","DOI":"10.7860\/JCDR\/2022\/57878.16719"},{"key":"5983_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1378\/chest.123.1.102","volume":"123","author":"L McNeill","year":"2003","unstructured":"McNeill L, Allen M, Estrada C, Cook P (2003) Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis. Chest 123:102\u2013106. https:\/\/doi.org\/10.1378\/chest.123.1.102","journal-title":"Chest"},{"key":"5983_CR26","volume-title":"Guide de lutte contre la tuberculose","author":"Minist\u00e8re de la Sant\u00e9 du Maroc","year":"2011","unstructured":"Minist\u00e8re de la Sant\u00e9 du Maroc (2011) Guide de lutte contre la tuberculose, 4th edn. Minist\u00e8re de la Sant\u00e9 du Maroc, Rabat","edition":"4th edn"},{"key":"5983_CR27","volume-title":"Plan strat\u00e9gique national pour la pr\u00e9vention et le contr\u00f4le de la tuberculose au Maroc 2018\u20132021","author":"Minist\u00e8re de la Sant\u00e9 du Maroc","year":"2018","unstructured":"Minist\u00e8re de la Sant\u00e9 du Maroc (2018) Plan strat\u00e9gique national pour la pr\u00e9vention et le contr\u00f4le de la tuberculose au Maroc 2018\u20132021. Minist\u00e8re de la Sant\u00e9, Rabat"},{"key":"5983_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ejcdt.2017.10.006","volume":"66","author":"RM Nafae","year":"2017","unstructured":"Nafae RM, Elshahat HM, Said AM, Ibrahim MA (2017) Reviewing treatment outcomes of tuberculosis patients at Zagazig Chest Hospital (2008\u20132012). Egypt J Chest Dis Tuberc 66:623\u2013630. https:\/\/doi.org\/10.1016\/j.ejcdt.2017.10.006","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"5983_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0962-8479(96)90073-8","volume":"77","author":"LP Ormerod","year":"1996","unstructured":"Ormerod LP, Horsfield N (1996) Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 77:37\u201342. https:\/\/doi.org\/10.1016\/S0962-8479(96)90073-8","journal-title":"Tuber Lung Dis"},{"key":"5983_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijtb.2019.11.005","volume":"66","author":"R Prasad","year":"2019","unstructured":"Prasad R, Singh A, Gupta N (2019) Adverse drug reactions in tuberculosis and management. Indian J Tuberc 66:520\u2013532. https:\/\/doi.org\/10.1016\/j.ijtb.2019.11.005","journal-title":"Indian J Tuberc"},{"key":"5983_CR31","first-page":"780","volume":"6","author":"T Santha","year":"2002","unstructured":"Santha T, Garg R, Frieden TR, Chandrasekaran V, Subramani R, Gopi PG et al (2002) Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 6:780\u2013788","journal-title":"Int J Tuberc Lung Dis"},{"key":"5983_CR32","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM et al (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935\u2013952. https:\/\/doi.org\/10.1164\/rccm.200510-1666ST","journal-title":"Am J Respir Crit Care Med"},{"key":"5983_CR33","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","volume":"9","author":"T Schaberg","year":"1996","unstructured":"Schaberg T, Rebhan K, Lode H (1996) Risk factors for side effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9:2026\u20132030. https:\/\/doi.org\/10.1183\/09031936.96.09102026","journal-title":"Eur Respir J"},{"key":"5983_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038273","volume":"103","author":"C Shi","year":"2024","unstructured":"Shi C, Yang B, Yang J, Song W, Chen Y, Zhang S et al (2024) Evaluation of adverse reactions induced by anti-tuberculosis drugs among hospitalized patients in Wuhan, China: a retrospective study. Medicine (Baltimore) 103:e38273. https:\/\/doi.org\/10.1097\/MD.0000000000038273","journal-title":"Medicine (Baltimore)"},{"key":"5983_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294490","volume":"18","author":"H-J Shin","year":"2023","unstructured":"Shin H-J, Yoon J-Y, Na Y-O, Lee J-K, Kho BG, Kim T-O et al (2023) Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment. PLoS ONE 18:e0294490. https:\/\/doi.org\/10.1371\/journal.pone.0294490","journal-title":"PLoS ONE"},{"key":"5983_CR36","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.cegh.2015.10.005","volume":"3","author":"A Singh","year":"2015","unstructured":"Singh A, Prasad R, Balasubramanian V, Gupta N, Gupta P (2015) Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clin Epidemiol Glob Health 3:S80\u2013S90. https:\/\/doi.org\/10.1016\/j.cegh.2015.10.005","journal-title":"Clin Epidemiol Glob Health"},{"key":"5983_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1378\/chest.99.2.465","volume":"99","author":"MA Steele","year":"1991","unstructured":"Steele MA, Burk RF, DesPrez RM (1991) Toxic hepatitis with isoniazid and rifampin. Chest 99:465\u2013471. https:\/\/doi.org\/10.1378\/chest.99.2.465","journal-title":"Chest"},{"key":"5983_CR38","first-page":"143","volume":"62","author":"WC Tan","year":"2007","unstructured":"Tan WC, Ong CK, Lo KSC, Razak MA (2007) Two-year review of cutaneous adverse drug reactions from first-line anti-tuberculous drugs. Med J Malaysia 62:143\u2013146","journal-title":"Med J Malaysia"},{"key":"5983_CR39","unstructured":"Taytard A (2005) Classement OMS des grades de toxicit\u00e9. F\u00e9d\u00e9ration Girondine de Lutte contre les Maladies Respiratoires (FGLMR). Available at: http:\/\/www.respir.com\/doc\/abonne\/pathologie\/cancerbronchique\/CBClassementOMSGradesToxicite.asp. Accessed 23 Aug 2025"},{"key":"5983_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/1471-2458-9-371","volume":"9","author":"B Tessema","year":"2009","unstructured":"Tessema B, Muche A, Bekele A, Reissig D, Emmrich F, Sack U (2009) Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia: a five-year retrospective study. BMC Public Health 9:371. https:\/\/doi.org\/10.1186\/1471-2458-9-371","journal-title":"BMC Public Health"},{"key":"5983_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1078-0432.CCR-13-2261","volume":"20","author":"BA Toll","year":"2014","unstructured":"Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL et al (2014) Quitting smoking will benefit your health: the evolution of clinician messaging to encourage tobacco cessation. Clin Cancer Res 20:301\u2013309. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2261","journal-title":"Clin Cancer Res"},{"key":"5983_CR42","unstructured":"Verma R, GR M, Shrivastava AK, Pathak P (2014) Adverse drug reactions associated with first-line anti-tubercular drugs in a tertiary care hospital of central India: a study of clinical presentations, causality, and severity. Asian J Pharm Clin Res 7:140\u2013143"},{"key":"5983_CR43","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1590\/S1806-37132008001200010","volume":"34","author":"DEO Vieira","year":"2008","unstructured":"Vieira DEO, Gomes M (2008) Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of S\u00e3o Paulo, Brazil. J Bras Pneumol 34:1049\u20131055. https:\/\/doi.org\/10.1590\/S1806-37132008001200010","journal-title":"J Bras Pneumol"},{"key":"5983_CR44","volume-title":"Global tuberculosis control 2008: surveillance, planning, financing","author":"World Health Organization","year":"2008","unstructured":"World Health Organization (2008) Global tuberculosis control 2008: surveillance, planning, financing. World Health Organization, Geneva"},{"key":"5983_CR45","volume-title":"Definitions and reporting framework for tuberculosis\u20142013 revision: updated December 2014 and January 2020","author":"World Health Organization","year":"2013","unstructured":"World Health Organization (2013) Definitions and reporting framework for tuberculosis\u20142013 revision: updated December 2014 and January 2020. World Health Organization, Geneva"},{"key":"5983_CR46","unstructured":"World Health Organization (2024) Global tuberculosis report 2024. World Health Organization, Geneva. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024. Accessed 3 Aug 2025"},{"key":"5983_CR47","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","volume":"167","author":"D Yee","year":"2003","unstructured":"Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167:1472\u20131477. https:\/\/doi.org\/10.1164\/rccm.200206-626OC","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05983-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:37:46Z","timestamp":1791268666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05983-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":47,"alternative-id":["5983"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05983-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Regional Health and Social Protection Directorate of La\u00e2youne Sakia El Hamra and by the Directorate of the Higher Institute of Nursing Professions and Health Technics of La\u00e2youne. All patients\u2019 data were collected anonymous. This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and complied with international ethical standards for research involving human participants.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}